Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

por Bray, J, Sludden, J, Griffin, M J, Cole, M, Verrill, M, Jamieson, D, Boddy, A V
Publicado 2010

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.

por McLeod, H. L., Sludden, J., Murray, G. I., Keenan, R. A., Davidson, A. I., Park, K., Koruth, M., Cassidy, J.
Publicado 1998

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

por Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., Canney, P., Fernandez-Salguero, P., Gonzalez, F. J., Cassidy, J., McLeod, H. L.
Publicado 1998

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

por Twelves, C J, Gardner, C, Flavin, A, Sludden, J, Dennis, I, Bono, J de, Beale, P, Vasey, P, Hutchison, C, Macham, M A, Rodriguez, A, Judson, I, Bleehen, N M
Publicado 1999

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

por Plummer, R, Wilson, R H, Calvert, H, Boddy, A V, Griffin, M, Sludden, J, Tilby, M J, Eatock, M, Pearson, D G, Ottley, C J, Matsumura, Y, Kataoka, K, Nishiya, T
Publicado 2011